Heart Failure Clinical Trial
— AUGMENT-HFOfficial title:
A Randomized, Controlled Study to Evaluate the Safety and Cardiovascular Effects of Algisyl-LVR™ as a Method of Left Ventricular Augmentation in Patients With Dilated Cardiomyopathy (AUGMENT-HF)
Verified date | March 2017 |
Source | LoneStar Heart, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a pilot study to evaluate the safety and efficacy of the Algisyl-LVR™ device. The
purpose of this study is to investigate Algisyl-LVR™ employed as a method of left
ventricular augmentation and restoration in patients with dilated cardiomyopathy.
Algisyl-LVR™ will be injected into the myocardium under direct visualization during the
surgical procedure.
This study will evaluate the concept that direct mid left ventricular (LV) intramyocardial
injections of Alginate hydrogel implants into the free wall of the failing LV will reduce LV
size, restore LV shape, lower LV wall stress and improve global LV function.
The Primary Efficacy Endpoint of the study is the change in Peak VO2 (maximum oxygen uptake)
from baseline to 6 months of follow-up. The Primary Safety Endpoint of the study is to
estimate the 30 day mortality associated with the implantation of the Algisyl-LVR device
The hypothesis of the study is that there is a statistically significant difference in
change in Peak VO2 from baseline to 6 month follow-up when the medically managed arm is
compared to the Algisyl-LVR arm, i.e. the Algisyl LVR arm is superior to medical management.
Status | Completed |
Enrollment | 78 |
Est. completion date | May 2016 |
Est. primary completion date | April 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 79 Years |
Eligibility |
Inclusion Criteria: 1. The patients must be able and willing to give written informed consent 2. The patients will be adult (age = 18 years and = 79 years) males or females 3. The patients must be on stable, evidence-based therapy for heart failure * Note: CRT or CRT-D are acceptable co-therapy, if placed > 3 months before randomization or the investigator does not anticipate within 6 months after randomization 4. The patients will have a left ventricular ejection fraction equal to or less than 35% via echocardiography, cardiac catheterization, radionuclide scan, or magnetic resonance imaging (measured within the last 30 days) 5. The patients will have a left ventricular end diastolic dimension indexed to body surface area (LVEDDi) of 30 to 40mm/m2 (LVEDD/BSA) (measured within the last 30 days) 6. Patients must have symptomatic heart failure with a Peak VO2 of 9.0 - 14.5 ml/min/kg (performed using a bicycle ergometer). Patients must perform two CPX tests (within 30 days of randomization and performed at least 20 hours apart) that differ by no more than 15% in the observed value for Peak VO2 and have a mean value of 9.0 - 14.5 ml/min/kg from these two tests. 7. Patient's surgical risk must be considered reasonable and the evaluation of surgical risk should include review of coronary and left ventricular angiography 8. If female, the patients must be (a) post-menopausal, (b) surgically sterile, or (c) using adequate birth control and have a negative serum pregnancy test within 7 days prior to administration of study device Exclusion Criteria: 1. Patients for whom it is planned to receive CABG, MVR, heart transplantation or LVAD within the next 6 months. 2. Patients presenting with cardiogenic shock. 3. Patients who have undergone a previous mid-sternotomy surgical procedure are excluded unless the surgeon's assessment is that the left sided limited thoracotomy is feasible and considered reasonable surgical risk. 4. Patients presenting with a restrictive cardiomyopathy such as due to amyloidosis, sarcoidosis, or hemochromatosis 5. Patient with a history of constrictive pericarditis 6. Patients with a Q wave myocardial infarction (MI) within the last 30 days 7. Patients with a recent history of stroke (within 60 days prior to the surgical procedure) 8. A left ventricular (LV) wall thickness of the LV free-wall, at the mid-ventricular level, of less than 8 mm (screening echocardiography must confirm a minimum wall thickness of 8 mm) 9. Patients with a serum creatinine > 2.5 mg/dL 10. Clinically significant liver enzyme abnormalities, i.e., AST(SGOT) and ALT (SGPT) more than 2.5 times the upper limit of normal 11. History of severe COPD (i.e., FEV 1< 1 liter or FEV1 < 50% predicted) 12. The patients will not be receiving concurrently an investigational Product in another clinical trial or have received an investigational Product in another clinical trial in the 30 days prior to enrollment 13. A life expectancy of less than 1 year or any other condition that, in the opinion of the clinical investigator, might compromise any aspect of the trial |
Country | Name | City | State |
---|---|---|---|
Australia | Heart Center at the Alfred | Melbourne | Victoria |
Germany | Charité (Campus Virchov) | Berlin | |
Germany | Charité - Universitätsmedizin Berlin (Campus Benjamin Franklin) | Berlin | |
Germany | Herzzentrum Dresden Universitätsklinik | Dresden | |
Germany | Universität Schleswig-Holstein Campus Kiel | Kiel | |
Germany | Universitätsklinikum Ulm | Ulm | |
Italy | Ospedali riuniti Dipartimento Cardiovascolare | Bergamo | |
Italy | Istituti Ospitalieri di Cremona | Cremona | |
Italy | Istituto Scientifico Universitario San Raffaele | Milan | |
Italy | Azienda Ospedaliera di Padova | Padova | |
Italy | IRCCS San Raffaele Roma | Rome | |
Italy | Policlinico Umberto I | Rome | |
Italy | IRCCS Policlinico San Donato | San Donato | Milanese (MI) |
Netherlands | St. Antonius Ziekenhuis Nieuwegein | Nieuwegein | |
New Zealand | Auckland City Hospital | Auckland | |
Romania | Centrului Clinic de Urgenta de Boli Cardiovasculare al Armatei | Bucharest | |
Romania | Clinica de Cardiologie, Spitalul Clinic de Urgenta "Sf. Pantelimon" | Bucharest | |
Romania | Spitalul Clinic De Urgenta MAI "Prof. Dr. Dimitrie Gerota" | Bucharest |
Lead Sponsor | Collaborator |
---|---|
LoneStar Heart, Inc. |
Australia, Germany, Italy, Netherlands, New Zealand, Romania,
Anker SD, Coats AJ, Cristian G, Dragomir D, Pusineri E, Piredda M, Bettari L, Dowling R, Volterrani M, Kirwan BA, Filippatos G, Mas JL, Danchin N, Solomon SD, Lee RJ, Ahmann F, Hinson A, Sabbah HN, Mann DL. A prospective comparison of alginate-hydrogel wi — View Citation
Mann DL, Lee RJ, Coats AJ, Neagoe G, Dragomir D, Pusineri E, Piredda M, Bettari L, Kirwan BA, Dowling R, Volterrani M, Solomon SD, Sabbah HN, Hinson A, Anker SD. One-year follow-up results from AUGMENT-HF: a multicentre randomized controlled clinical tria — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | peak VO2 | The primary effectiveness endpoint will be a comparison of change in Peak VO2 from baseline to 6 months of follow-up between the Algisyl-LVR and medically managed arms with the intention to prove superiority in improvement in Peak VO2 associated with the Algisyl-LVR study group as compared to the medically managed study group. Evaluation of the cardiopulmonary exercise testing will be conducted by a central, blinded core laboratory. | 6 months | |
Secondary | 30 day all cause mortality | The primary safety objective is to estimate the 30 day cardiac mortality associated with the implantation of the Algisyl-LVR device and qualitatively compare the observed rate to literature estimates for similar patients undergoing cardiac surgeries comparable in risk to implantation of the Algisyl-LVR | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|